February 7, 2023

George Vradenburg – The Future of Alzheimer’s Advocacy Part 2

George Vradenburg – The Future of Alzheimer’s Advocacy Part 2

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative. They explore the implications of the approval of Lecanemab (or Leqembi) worldwide and whether the approval encourages healthy at-risk adults 50 plus to understand their dementia risk profile.

BrainStorm Feed

86

Muffy Walker, Author of "Memory Weavers"

In this episode of BrainStorm by UsAgainstAlzheimer's Muffy Walker, a psychiatric nurse, founder of the International Bipolar Foundation, and autho

LISTEN NOW
85

Trump’s Policies and the Effect on Alzheimer's with George Vradenburg and Russ Paulsen

In this episode of the "BrainStorm" by UsAgainstAlzheimer's, George Vradenburg, Co-founder and Chairman of UsAgainstAlzheimer's, and Russ Paulsen,

LISTEN NOW
84

Greg O'Brien – Advocating for Scientific Research for Alzheimer’s

Journalist and author Greg O'Brien, diagnosed with early-onset Alzheimer's over a decade ago, shares with BrainStorm host Meryl his determination t

LISTEN NOW